Meryl Stav

Meryl Stav

Auto-generated profile, based on publicly available information

Meryl Stav

Department of Medicine, Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PKPriyadarshini Kachroo
Priyadarshini Kachroo
ISIsobel D. Stewart
Isobel D. Stewart
Rachel KellyRachel Kelly
Rachel Kelly
MSMeryl Stav
Meryl Stav
KMKevin Mendez
Kevin Mendez
Jessica Lasky-SuJessica Lasky-Su
Jessica Lasky-Su

19 January 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
YCYulu Chen
Yulu Chen
PZPei Zhang
Pei Zhang
MHMengna Huang
Mengna Huang
PKPriyadarishini Kachroo
Priyadarishini Kachroo
ACAntonio Checa
Antonio Checa
Jessica Lasky-SuJessica Lasky-Su
Jessica Lasky-Su
The lack of biomarkers to identify individuals at risk of asthma exacerbations remains a significant limitation to improving patient outcomes. To address this need, we analyze data from three asthma cohorts, combining up to 25 years of electronic medical records with sequential metabolomics studies, to develop and replicate a predictive model for asthma exacerbation risk. We identify asthma-associated biochemical pathways via global circulatory metabolomics and then apply targeted mass spectrometry methods to quantify selected steroids, sphingolipids, and microbial-derived metabolites. The sphingolipid-to-steroid ratios robustly associate with 5-year exacerbation risk (discovery p value = 1.63×10⁻26-0.029; replication p value = 1.89×10⁻36-0.033). Based upon these findings, we derive and replicate a simple 5-year predictive model of asthma exacerbations using 21 sphingolipid-to-steroid ratios that outperforms current clinical measures (discovery AUC = 0.90; replication AUC = 0.89). These findings underscore the value of metabolomic profiling to develop a practical, cost-effective clinical assay for asthma exacerbation risk that may improve patient care.

20 July 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
PKPriyadarshini Kachroo
Priyadarshini Kachroo
ISIsobel D. Stewart
Isobel D. Stewart
Rachel KellyRachel Kelly
Rachel Kelly
MSMeryl Stav
Meryl Stav
KMKevin Mendez
Kevin Mendez
Jessica Lasky-SuJessica Lasky-Su
Jessica Lasky-Su

1 May 2023
Verified
Conference Paper
Closed access
ASA. Saferali
A. Saferali
MSM. Stav
M. Stav
CLC. Liu
C. Liu
MCM.H. Cho
M.H. Cho
CHChristina Lee Hersh
Christina Lee Hersh
YTYohannes Tesfaigzi
Yohannes Tesfaigzi